These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

839 related items for PubMed ID: 23000100

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N, Kondo Y, Odkhuu E, Ulziisaikhan J, Ukaji T, Yokochi T, Umezawa K.
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [Abstract] [Full Text] [Related]

  • 5. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH.
    Eur J Pharmacol; 2009 Nov 25; 623(1-3):22-9. PubMed ID: 19766111
    [Abstract] [Full Text] [Related]

  • 6. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
    Park CK, Kim HJ, Kwak HB, Lee TH, Bang MH, Kim CM, Lee Y, Chung DK, Baek NI, Kim J, Lee ZH, Kim HH.
    Int Immunopharmacol; 2007 Dec 05; 7(12):1507-16. PubMed ID: 17920527
    [Abstract] [Full Text] [Related]

  • 7. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L, Lee J, Jang JH, Lee SH, Nan MH, Oh BC, Lee SG, Kim HH, Soung NK, Ahn JS, Kim BY.
    Bone; 2012 Jun 05; 50(6):1207-13. PubMed ID: 22484180
    [Abstract] [Full Text] [Related]

  • 8. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.
    Biochem Pharmacol; 2013 Sep 15; 86(6):782-90. PubMed ID: 23928189
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.
    J Bone Miner Res; 2005 Apr 15; 20(4):653-62. PubMed ID: 15765185
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.
    Choi HJ, Park YR, Nepal M, Choi BY, Cho NP, Choi SH, Heo SR, Kim HS, Yang MS, Soh Y.
    Eur J Pharmacol; 2010 Jun 25; 636(1-3):28-35. PubMed ID: 20353769
    [Abstract] [Full Text] [Related]

  • 12. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M, Choi HJ, Choi BY, Yang MS, Chae JI, Li L, Soh Y.
    Eur J Pharmacol; 2013 Sep 05; 715(1-3):96-104. PubMed ID: 23791609
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
    Han KY, Yang D, Chang EJ, Lee Y, Huang H, Sung SH, Lee ZH, Kim YC, Kim HH.
    Biochem Pharmacol; 2007 Sep 15; 74(6):911-23. PubMed ID: 17662251
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression.
    Kwak HB, Lee BK, Oh J, Yeon JT, Choi SW, Cho HJ, Lee MS, Kim JJ, Bae JM, Kim SH, Kim HS.
    Bone; 2010 Mar 15; 46(3):724-31. PubMed ID: 19900598
    [Abstract] [Full Text] [Related]

  • 15. Lanthanum Chloride Attenuates Osteoclast Formation and Function Via the Downregulation of Rankl-Induced Nf-κb and Nfatc1 Activities.
    Jiang C, Shang J, Li Z, Qin A, Ouyang Z, Qu X, Li H, Tian B, Wang W, Wu C, Wang J, Dai M.
    J Cell Physiol; 2016 Jan 15; 231(1):142-51. PubMed ID: 26060084
    [Abstract] [Full Text] [Related]

  • 16. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J, Park OJ, Lee YJ, Jung HM, Woo KM, Choi Y.
    Eur J Immunol; 2008 Jun 15; 38(6):1598-609. PubMed ID: 18421790
    [Abstract] [Full Text] [Related]

  • 17. OA10 is a novel p38alpha mitogen-activated protein kinase inhibitor that suppresses osteoclast differentiation and bone resorption.
    Jiang T, Qin A, Shao ZY, Tian B, Zhai ZJ, Li HW, Zhu ZA, Dai KR, Ming HZ, Yu YP, Jiang Q.
    J Cell Biochem; 2014 May 15; 115(5):959-66. PubMed ID: 24357524
    [Abstract] [Full Text] [Related]

  • 18. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.
    J Bone Miner Res; 2011 Mar 15; 26(3):644-56. PubMed ID: 20814972
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E, Koide N, Haque A, Tsolmongyn B, Naiki Y, Hashimoto S, Komatsu T, Yoshida T, Yokochi T.
    Immunol Lett; 2012 Feb 29; 142(1-2):34-40. PubMed ID: 22193059
    [Abstract] [Full Text] [Related]

  • 20. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.
    Kim AR, Kim HS, Lee JM, Choi JH, Kim SN, Kim DK, Kim JH, Mun SH, Kim JW, Jeon HS, Kim YM, Choi WS.
    Eur J Pharmacol; 2012 May 05; 682(1-3):29-36. PubMed ID: 22387094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.